

Use of Cysteamine in the Treatment of Cystinosis

NCT00359684

Status RECRUITING
Sponsor National Human Genome Research Institute (NHGRI)
Enrollment 330 participants

Key Eligibility Criteria

Inclusion (2)

- Diagnosis of cystinosis, whether classical or one of the variants with later onset or no renal complications.
- Patients will be diagnosed as having cystinosis based upon a leucocyte cystine content greater than 1 nmol half-cystine/mg protein (normal, less than 0.2) and a typical clinical course.

Exclusion (3)

- Inability to travel to the NIH.
- Age less than one week.
- Nonviable neonates and neonates of uncertain viability will be excluded.

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States